BioCentury | Feb 1, 2020
Tools & Techniques

Rosenberg study opens wider door to personalized TCR therapies for cancer

A new study from TIL pioneer Steve Rosenberg adds to the momentum of personalized T cell therapies by suggesting blood can be as good a source of neoantigen-specific TCRs as tumor tissue. The results, which...
BC Extra | Jan 29, 2020
Preclinical News

Rosenberg study highlights opportunity for blood-based take on TILs against mutant p53

A new study from TIL pioneer Steve Rosenberg adds to the momentum of blood-derived personalized T cell therapies by showing concordance between T cell responses against common p53 mutations in patients’ solid tumors and those...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

BioCentury, like the biomedical innovation ecosystem it serves, is relentlessly focused on the future, but the turn of a decade is a good time to check in on the progress industry has made possible --...
BioCentury | Nov 22, 2019
Emerging Company Profile

Morphiex’s antisense take on CD47 aims for more than eating

Morphiex is breaking from the CD47 pack by undercutting the target’s expression on both tumor and immune cells instead of just blocking tumors’ “don’t eat me” signals via SIRPA. The company believes its antisense approach...
BC Innovations | Nov 5, 2019
Product Development

Preprint study renews cancer fears for CRISPR-based therapies

CRISPR therapeutics companies have been quick to bounce back from each of the gene editing technology’s safety concerns originating from preprint publications in the past two and a half years, but a new paper adds...
BC Innovations | Oct 17, 2019
Product Development

Horizon 2020’s successor aims for improved uptake of innovation

The European Commission is in the midst of creating Horizon Europe, the successor to Horizon 2020, and this time around it aims to do more to ensure technologies created through the program are advanced by...
BC Extra | Oct 9, 2019
Company News

GSK partners with Lyell to bring gene, cell therapies into solid tumors

As GSK looks to expand its cell and gene therapy pipeline, the pharma has partnered with Lyell to take the modalities into solid tumors by improving T cell functionality and manufacturing. Lyell Immunopharma Inc. is...
BC Extra | Oct 1, 2019
Politics & Policy

Trump to nominate Hahn as FDA commissioner

President Donald Trump has decided to nominate Stephen Hahn as FDA commissioner, sources familiar with the decision told BioCentury. Hahn, chief medical executive of the University of Texas MD Anderson Cancer Center, is HHS Secretary...
BC Innovations | Sep 19, 2019
Translation in Brief

Public funding highlights

Public funding highlights Selected developments and initiatives in 2Q19 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
BC Extra | Aug 29, 2019
Preclinical News

Aug. 29 Preclinical Quick Takes: New targets for leukemia from Calico and stroke from Gero; predictors of checkpoint inhibitor response and more

Calico finds new target for sensitizing leukemia to NK cells  Calico Life Sciences LLC (South San Francisco, Calif.) showed in an eLife paper that blocking DCAF15, an adaptor for E3 ubiquitin ligase substrates, could boost...
Items per page:
1 - 10 of 1338
BioCentury | Feb 1, 2020
Tools & Techniques

Rosenberg study opens wider door to personalized TCR therapies for cancer

A new study from TIL pioneer Steve Rosenberg adds to the momentum of personalized T cell therapies by suggesting blood can be as good a source of neoantigen-specific TCRs as tumor tissue. The results, which...
BC Extra | Jan 29, 2020
Preclinical News

Rosenberg study highlights opportunity for blood-based take on TILs against mutant p53

A new study from TIL pioneer Steve Rosenberg adds to the momentum of blood-derived personalized T cell therapies by showing concordance between T cell responses against common p53 mutations in patients’ solid tumors and those...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

BioCentury, like the biomedical innovation ecosystem it serves, is relentlessly focused on the future, but the turn of a decade is a good time to check in on the progress industry has made possible --...
BioCentury | Nov 22, 2019
Emerging Company Profile

Morphiex’s antisense take on CD47 aims for more than eating

Morphiex is breaking from the CD47 pack by undercutting the target’s expression on both tumor and immune cells instead of just blocking tumors’ “don’t eat me” signals via SIRPA. The company believes its antisense approach...
BC Innovations | Nov 5, 2019
Product Development

Preprint study renews cancer fears for CRISPR-based therapies

CRISPR therapeutics companies have been quick to bounce back from each of the gene editing technology’s safety concerns originating from preprint publications in the past two and a half years, but a new paper adds...
BC Innovations | Oct 17, 2019
Product Development

Horizon 2020’s successor aims for improved uptake of innovation

The European Commission is in the midst of creating Horizon Europe, the successor to Horizon 2020, and this time around it aims to do more to ensure technologies created through the program are advanced by...
BC Extra | Oct 9, 2019
Company News

GSK partners with Lyell to bring gene, cell therapies into solid tumors

As GSK looks to expand its cell and gene therapy pipeline, the pharma has partnered with Lyell to take the modalities into solid tumors by improving T cell functionality and manufacturing. Lyell Immunopharma Inc. is...
BC Extra | Oct 1, 2019
Politics & Policy

Trump to nominate Hahn as FDA commissioner

President Donald Trump has decided to nominate Stephen Hahn as FDA commissioner, sources familiar with the decision told BioCentury. Hahn, chief medical executive of the University of Texas MD Anderson Cancer Center, is HHS Secretary...
BC Innovations | Sep 19, 2019
Translation in Brief

Public funding highlights

Public funding highlights Selected developments and initiatives in 2Q19 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
BC Extra | Aug 29, 2019
Preclinical News

Aug. 29 Preclinical Quick Takes: New targets for leukemia from Calico and stroke from Gero; predictors of checkpoint inhibitor response and more

Calico finds new target for sensitizing leukemia to NK cells  Calico Life Sciences LLC (South San Francisco, Calif.) showed in an eLife paper that blocking DCAF15, an adaptor for E3 ubiquitin ligase substrates, could boost...
Items per page:
1 - 10 of 1338